obiltoxaximab (Anthim)
Jump to navigation
Jump to search
Indications
- treatment of inhalation anthrax in combination with antibacterial agents
- prevention of inhalational anthrax when alternative therapies are not available or not appropriate
Dosage
Adverse effects
- headache
- pruritus
- upper respiratory tract infections
- cough
- nasal congestion
- hives
- bruising
- swelling
- pain at the infusion site
- hypersensitivity, anaphylaxis
More general terms
References
- ↑ FDA News. March 21, 2016 FDA approves new treatment for inhalation anthrax. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491470.htm